Trial Outcomes & Findings for A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection (NCT NCT02340078)

NCT ID: NCT02340078

Last Updated: 2019-01-23

Results Overview

The degree of pain was evaluated by VAS (Visual Analog Scale), measuring the length from the left and to the mark by the subject in millimeter (mm) unit.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

62 participants

Primary outcome timeframe

Visit 2 (week 0, immediately after treatment)

Results posted on

2019-01-23

Participant Flow

at 2 hospitals in korea, 62 patients. period : Nov 2013\~Feb 2015

spilt-face design. Subjects were decided by randomization which side of the face would be injected with the test device. According to this randomization result, the other side would be determined to be injected with a comparator. It was determined just by one randomization.

Participant milestones

Participant milestones
Measure
Subject Disposition
All Study Participants
Overall Study
STARTED
62
Overall Study
COMPLETED
61
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Subject Disposition
All Study Participants
Overall Study
Protocol Violation
1

Baseline Characteristics

A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Demographic Charateristics
n=62 Participants
Subjects who were included in efficacy evaluation
Age, Continuous
46.39 years
STANDARD_DEVIATION 7.03 • n=39 Participants
Sex/Gender, Customized
Female
62 participants
n=39 Participants
Sex/Gender, Customized
Male
0 participants
n=39 Participants

PRIMARY outcome

Timeframe: Visit 2 (week 0, immediately after treatment)

The degree of pain was evaluated by VAS (Visual Analog Scale), measuring the length from the left and to the mark by the subject in millimeter (mm) unit.

Outcome measures

Outcome measures
Measure
Subjects With at Least a 10mm Difference in VAS
n=62 Participants
Subjects with at least a 10mm difference in VAS (HA IDF II - HA IDF II plus)
Subjects With Below 10mm Difference in VAS
n=62 Participants
Subjects with below 10mm difference in VAS (HA IDF II - HA IDF II plus)
Proportion of the Subjects With at Least 10mm Difference in VAS Pain Scale Scores Within the Subject (VAS of the Control Device - VAS of the Test Device) Immediately After Treatment With the Investigational Devices
59 participants
3 participants

Adverse Events

Safety

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Safety
n=62 participants at risk
Subject who were injected with investigational medical device at least once. The 'Serious Adverse Events' and 'Other Adverse Events' described below occured in each subject regardless of the left or right of the injection site, and since all subjects were injected with both test device and comparator, it was not indicated which side the test device was injected.
General disorders
Administration Site Conditions
4.8%
3/62 • Number of events 3

Additional Information

Study Leader

LG Chem

Phone: 82-2-6987-4148

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER